Qubigen Joins the TBXT Challenge to Accelerate Discovery of Lead Candidates for Chordoma
- David Brooks
- 2 hours ago
- 1 min read
Qubigen is proud to announce its participation in the TBXT Challenge, a global initiative to develop lead drug candidates targeting the T-box transcription factor T (TBXT; also known as brachyury), an oncogenic driver in chordoma and other rare cancers.
Identification of promising lead molecules would open the door to exploring a collaborative relationship between Qubigen and the Chordoma Foundation, which has a strong interest in advancing therapeutics for targeting TBXT. Qubigen’s cutting-edge AI drug design platform is uniquely suited to generate novel, optimized candidates for this challenging target, while the Foundation brings extensive disease-specific knowledge, established capabilities for in vitro and in vivo evaluation, and a clinical trial network dedicated to chordoma. Together, this partnership could accelerate the path from hit identification to potential clinical candidates.
We are excited to contribute our technology and expertise to this important effort, and to explore new collaborative models that could lead to a tangible therapeutic impact for patients with chordoma.
Qubigen - accelerate drug design without exposing secrets.
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next discovery.